Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M706453200 on January 29, 2008

J. Biol. Chem., Vol. 283, Issue 16, 10500-10512, April 18, 2008
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Supplemental Data
Right arrow All Versions of this Article:
283/16/10500    most recent
M706453200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hayes, V. H.
Right arrow Articles by Quinlan, R. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hayes, V. H.
Right arrow Articles by Quinlan, R. A.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Truncation of {alpha}B-Crystallin by the Myopathy-causing Q151X Mutation Significantly Destabilizes the Protein Leading to Aggregate Formation in Transfected Cells*Formula

Victoria H. Hayes{ddagger}, Glyn Devlin§, and Roy A. Quinlan{ddagger}1

From the {ddagger}School of Biological and Biomedical Sciences, South Road Science Site, Durham University, Durham DH1 3LE and the §Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge CB2 1EW, United Kingdom

Received for publication, August 3, 2007 , and in revised form, January 29, 2008.


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Here we investigate the effects of a myopathy-causing mutation in {alpha}B-crystallin, Q151X, upon its structure and function. This mutation removes the C-terminal domain of {alpha}B-crystallin, which is expected to compromise both its oligomerization and chaperone activity. We compared this to two other {alpha}B-crystallin mutants (450delA, 464delCT) and also to a series of C-terminal truncations (E164X, E165X, K174X, and A171X). We find that the effects of the Q151X mutation were not always as predicted. Specifically, we have found that although the Q151X mutation decreased oligomerization of {alpha}B-crystallin and even increased some chaperone activities, it also significantly destabilized {alpha}B-crystallin causing it to self-aggregate. This conclusion was supported by our analyses of both the other disease-causing mutants and the series of C-terminal truncation constructs of {alpha}B-crystallin. The 450delA and 464delCT mutants could only be refolded and assayed as a complex with wild type {alpha}B-crystallin, which was not the case for Q151X {alpha}B-crystallin. From these studies, we conclude that all three disease-causing mutations (450delA, 464delCT, and Q151X) in the C-terminal extension destabilize {alpha}B-crystallin and increase its tendency to self-aggregate. We propose that it is this, rather than a catastrophic loss of chaperone activity, which is a major factor in the development of the reported diseases for the three disease-causing mutations studied here. In support of this hypothesis, we show that Q151X {alpha}B-crystallin is found mainly in the insoluble fraction of cell extracts from transient transfected cells, due to the formation of cytoplasmic aggregates.


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
The crystallins were first identified as the major proteins of the eye lens and their subsequent classification into {alpha}-, β-, and {gamma}-crystallins (1) allowed different functional properties to be assigned to the {alpha}- and β{gamma}-crystallin groups (2). The {alpha}-crystallins are two distinct proteins derived from two separate genes, {alpha}A- and {alpha}B-crystallin (2). Whereas {alpha}A-crystallin is almost entirely lens specific (3), {alpha}B-crystallin is expressed widely in other tissues, most notably astrocytes (4) and muscle (5). In the early 1980s, pioneering work from Klemenz and co-workers (6) and Horwitz (7) laboratories established that {alpha}B-crystallin was a protein chaperone and a member of the small heat shock protein (sHSP)2 family, that is now known to comprise 10 different human proteins (8).

When the first mutation (R120G) in {alpha}B-crystallin was reported, it was found to cause both cataract and desmin-related myopathy in the affected patients (9). Characteristic histopathological aggregates of the muscle intermediate filament protein desmin were observed (9), strongly suggesting that there is an important functional interaction between intermediate filaments and {alpha}B-crystallin. Subsequent analyses showed that the R120G {alpha}B-crystallin mutation induced increased binding for desmin intermediate filaments (10), providing an explanation for the formation of the desmin aggregates in the muscles of the affected individuals. Coincidentally, mutations in desmin also induced filament aggregation (11, 12) and these aggregates also contained {alpha}B-crystallin (12). Collectively, these data suggest that one of the functions of {alpha}B-crystallin is to chaperone intermediate filaments and their networks in cells (10, 13, 14).

Subsequently, three other mutations in the C-terminal extension were reported for {alpha}B-crystallin, but in contrast to the R120G mutation, none caused both cataract and myopathy. The first of these was the 450delA mutation that is associated only with cataract and resulted in a 184-residue product where the coding sequence of the C-terminal extension was altered from residue 150 onwards (15). This region is distal to the β-strand 9 and proximal to the conserved hydrophobic IX(I/V) motif (16) that forms part of β-strand 10 in the crystal structure of the archaeal HSP16.5 (17). Two other mutations were then reported (Q151X and 464delCT) that cause myopathy and not cataract (18) that either truncated (Q151X) or substituted the C-terminal extension from residue 155 (464delCT). The fact that all three mutations delete a known substrate interaction site (157–164) (19) and a region important in the oligomerization of {alpha}B-crystallin itself (155–166) (20) support the hypothesis that this region in {alpha}B-crystallin is important to both the structure and function of the protein. Very recently, a C-terminal point mutation (R157H) (21) was reported, lending further support to this conclusion. Thus far, the effect of such extensive deletions (Q151X) combined with altered C-terminal sequences (450delA and 464CT) upon {alpha}B-crystallin structure and function have not been investigated.

In other sHSPs, the C-terminal domain has been shown to be very important to both oligomerization and chaperone function and therefore the expectation is that the C-terminal extension mutations would similarly affect {alpha}B-crystallin. Removal of the 17 most C-terminal residues of {alpha}A-crystallin reduced its chaperone activity and induced the formation of larger oligomers (22). In two crystal structures of sHSPs (HSP16.5 (17) and HSP16.9 (23)), the C-terminal extension makes contact with a hydrophobic patch on neighboring protein subunits, strengthening the dimer-dimer interaction in the oligomer (23). The sequence between β-strands 9 and 10 of the C-terminal extension contains a hinge that likely contributes to the size polydispersity of the different sHSPs by allowing packing geometries to vary while maintaining common interaction surfaces (23). Some naturally occurring sHSPs lack a C-terminal extension and in such cases the oligomerization is restricted, as seen for Tsp36 from the tapeworm Taenia saginata, which forms dimers and tetramers, but is functional as a chaperone (24). Likewise, removal of the short C-terminal extension from Methanococcus janaschii HSP16.5 resulted in reduced oligomerization, but the retention of chaperone activity (25). This is quite contrary to the closely related lens chaperone {alpha}A-crystallin that naturally co-oligomerizes with {alpha}B-crystallin in the lens. Stepwise removal of C-terminal sequences from {alpha}A-crystallin, including the REEK motif, not only reduced oligomerization, but also resulted in the sequential loss of chaperone activity (26), despite the fact that the IX(I/V) motif was retained in the mutants investigated. Mutations of lysine and glutamic acid residues in the C-terminal extension can improve chaperone activity against amyloid fibril formation providing a potential application of {alpha}B-crystallin in the treatment of amyloid-related diseases (27). In {alpha}B-crystallin, there has not been any systematic analysis of the role of the C-terminal extension and therefore no potential explanation of whether the three mutations (450delA, Q151X, and 464delCT) cause the various diseases via the loss of chaperone function or perhaps by a different mechanism.

In this study, we have analyzed the effects of the Q151X, 464delCT, and 450delA upon the oligomerization and chaperone activity of {alpha}B-crystallin. For comparison, we have also assessed the activity of a series of {alpha}B-crystallin constructs truncated at residues Lys174, Ala171, Glu165, and Glu164 to sequentially remove important regions of the C-terminal extension and therefore help us understand the effect of the Q151X mutation. With respect to the role of the C-terminal extension in oligomerization, our data show similar results to those obtained for {alpha}A-crystallin (28). Interestingly, the chaperone function of Q151X is actually increased in some in vitro chaperone assays. The ability of Q151X {alpha}B-crystallin to resist self-aggregation is, however, very greatly diminished, a trend that is further enhanced by the 464delCT and 450delA mutations, which are only stable in the presence of wild type {alpha}B-crystallin. These data show that like other sHSPs, the C-terminal extension is important for oligomerization. Its removal increases the tendency of {alpha}B-crystallin to self-aggregate.


   EXPERIMENTAL PROCEDURES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
RESULTS
 DISCUSSION
 REFERENCES
 
Construction of {alpha}B-Crystallin Mutants
Primers (Table 1; Sigma Genosys, UK) were designed based on the mRNA sequence for wild type human {alpha}B-crystallin (DDBJ/EMBL/GenBank entry NM_001885 [GenBank] ) and were used to generate the mutants listed, using wild type {alpha}B-crystallin as a template for PCR mutagenesis. With the exception of the Q151X and E165X mutations, the amplified products were cloned into the vector pGEM®-T Easy (Promega). After verification of the sequences, the mutant {alpha}B-crystallin constructs were subcloned into the NcoI and EcoRI sites of the expression vector pET23d (Invitrogen). The Q151X and E165X mutations were introduced into pET23d by site-directed mutagenesis (Stratagene) using complementary primers (see Table 1). Constructs were sequenced and compared for fidelity to the GenBankTM data base (accession number NM001885).


View this table:
[in this window]
[in a new window]

  		TABLE 1
Oligonucleotide primer sequence details used for introduction of the {alpha}B-crystallin mutations

The unique restriction enzyme sites incorporated into the primer design are highlighted in bold text. Q151X and E165X were introduced using site-directed mutagenesis (SDM) requiring complementary forward (5'-3') and reverse (3'-5) primers. The 464delCT, K174X, A171X, and E164X mutant mRNA were amplified using a forward primer overlapping the pET23d insertion site and the 5' end of the template wild type {alpha}B-crystallin. Reverse primers were complementary to the 3' end of the template wild type {alpha}B-crystallin and incorporated the mutation and unique restriction sites to assist screening, using the available software (DNA_Analysis_Frame). A suitable restriction enzyme site was not available for the 464delCT mutation.

 
Protein Expression and Purification of {alpha}B-Crystallin Mutants
Proteins were recombinantly expressed in Escherichia coli strain BL21 (pLysS). The wild type {alpha}B-crystallin, K174X and A171X proteins were prepared essentially as described (29), but adding polyethyleneimine (final concentration 0.1% (w/v)) to remove contaminating DNA (10, 30) before purification by ion exchange chromatography on a Fractogel TMAE column. Peak fractions were pooled and then dialyzed into 20 mM Tris-HCl, 100 mM NaCl, pH 7.4, in preparation for size exclusion chromatography on a Fractogel EMD BioSEC Superformance column (60 x 1.6 cm; VWR, UK).

All other mutant {alpha}B-crystallins formed inclusion bodies, and were purified essentially as described (31). These were dissolved in 10 mM Tris-HCl, 6 M urea, 1 mM EDTA, pH 8.0, 0.2 mM phenylmethylsulfonyl fluoride, 1 mM dithiothreitol and then purified by ion exchange chromatography (29) on a Fractogel TMAE column.

Fractions containing {alpha}B-crystallin were pooled and sometimes concentrated using an Amicon Ultra Centrifugal filter device 10K MWCO (Millipore, Bedford, MA). Concentrations of the purified proteins were determined using BCA Protein Assay reagent kit (Pierce) unless otherwise stated.

Refolding of {alpha}B-Crystallin Mutants following Inclusion Body Purification
In the Presence of Wild Type {alpha}B-Crystallin
The 450delA, 464delCT, and Q151X were refolded in the presence of wild type {alpha}B-crystallin. Wild type {alpha}B-crystallin was dialyzed for 16 h at 4 °C into 10 mM Tris-HCl, 6 M urea, 1 mM EDTA, pH 8.0, 1 mM dithiothreitol. Protein concentration of the wild type and mutant {alpha}B-crystallin were determined by OD280 (extinction coefficients were determined using the Emboss Pepstats program) and then mixed in a 1:1 ratio.

Diluted Refold Protocol (450delA/Wild Type, Q151X/Wild Type, E164X, and Q151X)
The protein mixture was diluted to 0.25 mg/ml in 10 mM Tris-HCl, 6 M urea, 1 mM EDTA, pH 8.0, 1 mM dithiothreitol followed by an additional 6-fold dilution to 1 M urea in refold buffer (10 mM Tris-HCl, 5 mM EDTA, 1 mM EGTA, 150 mM NaCl, pH 7.5) prior to dialysis against the same buffer for 4 h at 16 °C. The dialysate was partially concentrated using Amicon Ultra Centrifugal filter device 10K MWCO (Millipore) and centrifuged for 2 h at 4°C at 250,000 x g in the Beckman Optima MAX Ultracentrifuge MLA-80 rotor (Beckman Instruments Inc., Fullerton, CA). The supernatant was further concentrated to a suitable volume.

Undiluted Refolding Protocol (464delCT/Wild Type, E165X)
The protein mixture was dialyzed into refold buffer for 4 h at 16 °C. The dialysate was centrifuged for 2 h at 4 °C at 250,000 x g in the Beckman Optima MAX Ultracentrifuge MLA-80 rotor (Beckman Instruments Inc.) and the supernatant concentrated to give the desired protein concentration.

Characterization of {alpha}B-Crystallin Mutants
Analytical Size Exclusion Chromatography (SEC)
Purified {alpha}B-crystallin proteins were analyzed using a Superose 6 column (290 x 10 mm) at a flow rate of 0.2 ml/min at room temperature using a Merck-Hitachi Biochromatography system. The data were analyzed using Chromeleon 6.30 software (Sunnyvale, CA).

Mass Spectrometry for Molecular Weight Determination
Purified proteins were loaded onto a MassPREP desalting cartridge (Waters, Elstree, Herts, UK) to remove buffer contaminants. The protein was eluted with 70% (v/v) acetonitrile, 0.5% (v/v) formic acid at 0.2 ml/min and introduced into a Waters Q-TOF Premier mass spectrometer operating in positive electrospray mode, with a cone voltage of 40 V. Spectra were externally calibrated using sodium formate, then corrected for drift using a leucine enkephalin lockspray. Multiply charged protein ions were deconvoluted using the manufacturer-supplied MaxEnt1 software, to determine protein mass.

CD Spectroscopy
Far UV CD spectra of wild type and mutant {alpha}B-crystallin were recorded in a cuvette with 0.1-cm path length at room temperature using a Jasco J-810 spectropolarimeter. Samples were at a concentration of 0.2–0.3 mg/ml, with the exception of Q151X, assayed at 0.1 mg/ml due to the low yield of soluble protein. Samples were assayed in 10 mM Tris, 150 mM NaCl, 5 mM EDTA, 1 mM EGTA, pH 7.5. Four data sets were collected for each sample and averaged, by continuous scanning at 100 nm/min, between wavelengths 190 and 250 nm. The UV CD spectra were baseline corrected using spectra of the buffer. The CD spectra were normalized and expressed as molar ellipticity.

Thermal Stability Assay
Absorbance at 360 nm over a temperature gradient of 25–86 °C at 1 °C/min ramp rate was continuously monitored using the Beckman DU640 spectrophotometer. Samples were assayed at 0.1 mg/ml.

In Vitro Protein Chaperone Assays
Citrate Synthase—A 200-µl volume of citrate synthase from porcine heart (Sigma) was dialyzed for 16 h at 4 °C against 50 mM Tris-HCl, 2 mM EDTA, pH 8.0, and diluted to 0.49 mg/ml. The assay mixture contained citrate synthase and {alpha}B-crystallin at a 4:1 ratio of substrate:chaperone in 220 µl. Time-dependant light scattering was measured at 360 nm every 15 s over 30 min at 42 °C using a Beckman DU640 spectrophotometer.

Insulin Assay—A 20-mg aliquot of insulin from bovine pancreas (Sigma) was reconstituted in 100 mM NaSO4, 20 mM NaPO4, pH 6.9 (Insulin buffer), and solubilized by the addition of 30% (v/v) acetic acid and gentle mixing for 15 min. The insulin solution was dialyzed for 16 h at 4 °C against the insulin buffer and the dialysate was centrifuged for 1 min at 13,000 x g in an Eppendorf bench top centrifuge (5417R; Eppendorf, Hamburg, Germany). The insulin concentration was determined from the measured OD280 using its extinction coefficient ((A280/5840) x 5600 = mg/ml). Insulin was mixed with {alpha}B-crystallin at a 4:1 ratio and the change in light scattering was measured at 360 nm every 15 s over a period of 15 min at 37 °C using a Beckman DU640 spectrophotometer.

Bis-ANS Fluorescence Measurements
{alpha}B-Crystallin variant proteins were incubated in 10 mM Tris, 150 mM NaCl, 5 mM EDTA, 1 mM EGTA, pH 7.5, at a protein concentration of 1 µM and in the presence of a 10-fold molar excess of bis-ANS (4,4'-dianilino-1,1'-binaphthyl-5,5'-disulfonic acid, purchased from Invitrogen). Samples were allowed to equilibrate for 1 h at room temperature prior to the acquisition of fluorescence spectra on a Varian Cary Eclipse fluorescence spectrophotometer. The excitation wavelength was 410 nm and emission was collected between 420 and 700 nm with excitation and emission slit widths of 5 nm and a scan speed of 600 nm/min. All spectra are the average of 10 individual scans.

In Vitro Desmin Filament Assembly and Cosedimentation Assay
In vitro assembly and cosedimentation assays were carried out essentially as described (10). Recombinant human desmin was a kind gift from Dr. Ming Der Perng (Durham, UK). Wild type or mutant {alpha}B-crystallin was mixed with desmin in low ionic strength buffer at a 1:1 mass ratio at 0.1 mg/ml. After filament assembly, samples were separated into pellet and supernatant fractions by high speed centrifugation (80,000 x g for 30 min at 20 °C in a Beckman TLS-55 rotor (Beckman Instruments Inc., Fullerton, CA)) as described (10) to pellet assembled desmin filament and the associated {alpha}B-crystallin. To investigate the ability of the three {alpha}B-crystallin mutants and the other C-terminal truncation constructs to prevent filament-filament interactions in vitro, an additional low-speed centrifugation assay was used (2500 x g for 15 min in a bench top centrifuge) as described previously (10). The pellet and supernatant fractions were analyzed by 12% (w/v) SDS-PAGE (32) and protein bands visualized by Coomassie Blue staining. The amount of protein in the supernatant and pellet fractions were analyzed by a luminescent image analyzer (LAS-1000plus; Fuji Film, Tokyo, Japan) and quantified using the Image Gauge software (version 4.0; Fuji Film).

Cell Cultures and Transient Transfection Assays
MCF7 cells were maintained as described previously (10). Wild type and mutant {alpha}B-crystallin were subcloned into the mammalian expression vector pcDNA3.1 (Invitrogen) from the bacterial expression vector pET23d, using XbaI and HindIII. Transient transfection of these cells was achieved using Gene-Juice transfection reagent (Novagen) according to manufacturer's protocol. Cells were allowed to recover for 24 h before processing for immunofluorescence microscopy, cell fractionation, and immunoblotting.

Cell Fractionation, SDS-PAGE, and Immunoblotting
Cells grown on 10-cm dishes were washed twice with phosphate-buffered saline before being lysed with 1 ml of extraction buffer (phosphate-buffered saline, 0.5% (v/v) Triton X-100) by repeatedly passing through a 25-gauge needle. Following incubation on ice for 15 min, the lysates were clarified by centrifugation 18,000 x g for 10 min at 4 °C. The resulting supernatant and pellet fractions were solubilized in equal volumes of Laemmli sample buffer before SDS-PAGE and immunoblotting analysis as described (10). Membranes were probed with a panel of purified mouse monoclonal anti-{alpha}B-crystallin 2D2B6 and monoclonal anti-HSP27 antibody, ER-D5, as described (10). Antibody labeling was detected by enhanced chemiluminescence using a luminescent image analyzer (LAS-1000plus; Fuji Photo Film (UK), London, United Kingdom).

Immunofluorescence Microscopy
Cells were processed as described previously (10). The primary antibodies used in this study were rabbit polyclonal anti-{alpha}B-crystallin, a synthetic peptide corresponding to human {alpha}B-crystallin residues 1–10 (MDIAIHHPWI) conjugated to hemocyanin (1:200; Chemicon Ab1546) and monoclonal mouse anti-keratin LE41 (1:1; CRUK). Samples were analyzed using an Axioplan fluorescence microscope (Carl Zeiss, Jena, Germany). Images were obtained using a confocal Axiovert 200M microscope and LSM 510 META software (both Zeiss, Germany). Optical sections were set to ~1.0 µm. Images were processed and prepared for figures using Adobe Photoshop 8.0 (Adobe Systems). Quantitation of the {alpha}B-crystallin phenotypes was by visual assessment of the cells.


   RESULTS
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
DISCUSSION
 REFERENCES
 
Expression and Purification of the C-terminal Extension {alpha}B-Crystallin Mutants—An overview of the C-terminal extension mutants in comparison to wild type {alpha}B-crystallin is presented (Fig. 1A). It shows the relationship of the various mutations and truncations to the structural features of the C-terminal extension and also summarizes the consequences of the two frameshift mutations, 450delA and 464delCT, that cause inherited cataract (15) and myofibrillar myopathy (18), respectively. In addition to the three disease-causing mutations (Q151X, 450delA, and 464delCT), a series of C-terminal extension truncation constructs were also expressed and purified (Fig. 1B). All the mutants except A171X and K174X were purified from inclusion bodies. The predicted mass of each of the expressed proteins was confirmed by mass spectrometry measurements (Fig. 1C). Whereas Q151X, E164X, and E165X could be refolded successfully without the addition of wild type {alpha}B-crystallin, both 450delA and 464delCT could only be refolded in its presence. When refolded with an equimolar ratio of {alpha}B-crystallin, ~7% of 450delA and 10% of 464delCT remained soluble (Fig. 1D). Although Q151X {alpha}B-crystallin could be refolded in the absence of wild type {alpha}B-crystallin, the yield could be increased some 7-fold when the wild type protein was included. These data show the disease-causing mutations seriously affect the solubility of {alpha}B-crystallin.


Figure 1
View larger version (38K):
[in this window]
[in a new window]

  		FIGURE 1.
Details of the {alpha}B-crystallin mutants and their characterization by SDS-PAGE. Structural alignment of the C-terminal extensions of {alpha}B-crystallin mutants (A) includes the C-terminal extension from residue 149 (24), and β-sheets and the IX(I/V) motif are indicated as black boxes. The β7 sequence spans residues 118–123 (FHRKYR), β8 sequence spans residues 134–138 (TSSLS), and β9 sequence spans residues 142–148 (VLTVNGP). The highly conserved IX(I/V) motif includes residues 159–161 (IPI). The C-terminal extension consists of residues 149–175 (RKQVSGPERTIPITREEKPAVTAAPKK). B, characterization of the bacterially expressed and purified mutants used in this study by SDS-PAGE. The 450delA (arrow) and 464delCT (arrowhead) mutants could not be produced as individual soluble proteins and therefore were refolded in the presence of wild type {alpha}B-crystallin. Molecular weight markers (track M) are indicated (•) in order of increasing relative mobility (40, 33, 24, and 17 kDa). The relative molecular weights of the wild type and mutant {alpha}B-crystallins (C) were confirmed by mass spectrometry and compared with values calculated from the amino acid sequences using the Emboss Pepstats program. D, refolding yields for {alpha}B-crystallin truncation constructs and mutants purified from inclusion bodies.

 
The K174X construct removes the two most C-terminal lysine residues and would be expected to retain the secondary structural characteristics and oligomerization characteristics of {alpha}B-crystallin (33). The electrophoretic mobility of this K174X mutant was increased relative to the wild type {alpha}B-crystallin (Fig. 1B) and is in agreement with previous observations for C-terminal-deleted forms of {alpha}B-crystallin (34–37). Removal of the 5 most C-terminal residues generated the A171X mutant and is equivalent to the truncated form of {alpha}B-crystallin found in normal rat lenses (38), bovine lenses (39), and in rat models of diabetic cataracts (40). Another C-terminal-truncated form of {alpha}B-crystallin (E164X) has 12 residues removed from the C terminus and this has been detected in normal rat lenses (41). This truncation deletes the pair of glutamic acid residues at positions 164 and 165 that are part of the REEK motif in {alpha}A-crystallin that have been shown to be important in oligomerization (26). It is also equivalent to the 10-residue C-terminal-truncated form of {alpha}A-crystallin (40).

Truncation of the C-terminal Extension Reduces {alpha}B-Crystallin Oligomerization—Wild type {alpha}B-crystallin formed oligomers that were equivalent to 564 kDa, as calculated from the size exclusion chromatography data, agreeing with previously published data (42). The oligomer population was consistent between different preparations as shown by dynamic light scattering (supplementary data Fig. S1). The sequential truncation of the C-terminal extension of {alpha}B-crystallin produces a steady decrease in oligomer size (Fig. 2A). The shortest construct Q151X {alpha}B-crystallin produces a peak with very significantly increased elution volume (Fig. 2B) and represents the most dramatic reduction in oligomerization observed for all the constructs studied. This effect on Q151X oligomerization is obvious when the negative stained electron micrographs of wild type and Q151X {alpha}B-crystallin are compared (Fig. 2, C and D, respectively). Notice the absence of particles in the Q151X sample (Fig. 2D) relative to the wild type (Fig. 2C).

Deletion of the two C-terminal lysines (K174X) did not alter significantly the oligomerization of {alpha}B-crystallin, as previously reported (33). Removal of 5 C-terminal residues, however, reduced the apparent size of the main peak, as did the removal of both 11 (E165X) and 12 (E164X) residues. In the case of the latter two truncation mutants, there is evidence of increased polydispersity as indicated by the very noticeable shoulder on the main peak for the E165X construct and the presence of an additional peak at the void volume of the column for the E164X construct. The elution volume of the main peak is increased, suggestive of reduced mean size for {alpha}B-crystallin oligomers. These data suggest that residues Glu164-Glu165 also contribute to {alpha}B-crystallin oligomerization.

The two frameshift mutants 450delA and 464delCT remained insoluble unless they were refolded in the presence of wild type {alpha}B-crystallin. As seen from the elution profiles in Fig. 2A, the presence of these mutant proteins decreased the oligomer size of the wild type {alpha}B-crystallin. SDS-PAGE analysis (Fig. 1B) revealed that the wild type {alpha}B-crystallin is present in excess compared with 450delA {alpha}B-crystallin, yet this excess was not sufficient to retain the elution characteristics of the wild type protein. In fact, this proved to be the maximum ratio compatible with protein solubility for the 450delA-wild type {alpha}B-crystallin complex and is in stark contrast to 464delCT {alpha}B-crystallin, where a 1:1 mixture with wild type {alpha}B-crystallin was entirely soluble. The presence of the 450delA {alpha}B-crystallin also increased the polydispersity of the main peak, as seen by the shoulder and the additional small peak with a predicted molecular weight equivalent to {alpha}B-crystallin dimers.

The 450delA mutation introduces a unique 33-residue polypeptide completely unrelated to the C-terminal extension of wild type {alpha}B-crystallin (Fig. 1A) and quite clearly this frame-shift sequence has a significant effect upon the oligomerization of {alpha}B-crystallin. It is, however, the Q151X mutation that has the most dramatic effect, with the complete removal of the single peak equivalent to the 564-kDa oligomer and the appearance of a peak with elution characteristics predicted to be equivalent to a monomer. Non-denaturing gel electrophoresis also confirmed that the Q151X mutation dramatically altered its electrophoretic mobility under non-denaturing conditions in line with significantly altered oligomerization (supplementary data Fig. 2).


Figure 2
View larger version (99K):
[in this window]
[in a new window]

  		FIGURE 2.
Effect of the Q151X mutation upon the oligomerization of {alpha}B-crystallin. The elution profiles of the various {alpha}B-crystallins were determined on a 290 x 10-mm Superose 6 column (A). The elution characteristics of the various mutants are plotted relative to those obtained for wild type {alpha}B-crystallin (wild type), as highlighted by the vertical line indicating the retention time of the oligomeric complex, which is the major and only peak resolved in the wild type {alpha}B-crystallin sample. Additional minor species seen in E164X and 450delA/wild type are highlighted. A summary of the retention times (B) is shown for the major peak resolved during SEC of the wild type{alpha}B-crystallin and other constructs. The retention times of minor peaks are included in the figure as appropriate. The retention times (±S.D.) were calculated from the average of three cycles of SEC. Negative stained images of wild type (C) and Q151X{alpha}B-crystallin (D) were obtained by transmission electron microscopy and illustrate the absence of characteristic particles in the Q151X sample, in agreement with the SEC data. Bar, 500 nm.

 
Effect of the C-terminal Mutations upon the Secondary Structure and Oligomerization of {alpha}B-Crystallin—CD spectroscopy of wild type {alpha}B-crystallin showed a single, broad minima, between 208 and 217 nm, indicative of a protein rich in β sheet (Fig. 3), which is consistent with previously reported data (42–46). The Q151X mutation had the most significant effect upon the far UV CD characteristics of {alpha}B-crystallin (Fig. 3), due to a very significant red shift of the minima to 217 nm and a ~50% reduction in magnitude, suggestive of a significant loss of secondary structure. Similar shift patterns have been seen for C-terminal truncation mutants of {alpha}A-crystallin (26). A 1:1 molar mixture of Q151X with {alpha}B-crystallin wild type produced a spectrum that was clearly biased toward the Q151X, indicative of the dominant nature of this mutation.

Of the other mutants studied, the E164X and E165X mutants were intermediate in their effects upon negative ellipticity as compared with the Q151X mutant. This intermediate effect is likely associated with the extent of the C-terminal truncations of E164X, E165X relative to Q151X, and suggests a less significant loss of secondary structure. Interestingly, the E164X mutant showed a red shift in the minimum indicating that the deletion of the second of the two glutamic acid residues in the REEK motif does introduce a detectable change in secondary structure. A recent study showed an R163X mutant with significantly altered secondary structure compared with the wild type (27). The frameshift mutation, 464delCT, introduced a small blue shift of the minimum to 208 nm and the appearance of a shoulder at ~223 nm, both of which are indicative of increased helicity. This increase may be the result of helix formation by the novel C-terminal sequence. Both the K174X and A171X truncation mutants and the 450delA frameshift mutant have far UV CD spectra very similar to the wild type {alpha}B-crystallin.

Loss in Heat Stability of {alpha}B-Crystallin Correlates with Changes in Secondary Structure—To probe the consequences of the altered secondary sequence characteristics of the {alpha}B-crystallin C-terminal extension mutants, their heat stability was determined (Fig. 4). These data show that the two most unstable mutants are E164X and E165X because both the onset and optical signal was very significantly increased compared with wild type {alpha}B-crystallin for these two mutants. The E164X mutant began to aggregate at 46 °C, some 30 °C lower than the wild type protein. The E165X mutant was notable for the rapidity of aggregation when initiated at 57 °C, whereas the Q151X mutant was notable in its failure to develop a strong OD360 signal, despite the very significant decrease in stability indicated by the increased turbidity at 53 °C. This signal reached a maximum at 55 °C and remained constant until the conclusion of the assay. The two shorter C-terminal truncations (K174X and A171X), showed decreased stability, but were the most stable of the constructs studied.

These data suggest a correlation between altered secondary structure and decreased heat stability. This trend is also seen for the two frameshift mutants (450delA/wild type and 464delCT/wild type) that were more stable than the three shortest constructs, but less stable than either the A171X or K174X truncation constructs. These data correlate with more conservative changes in secondary structure as detected by far UV CD spectroscopy for the two frameshift mutants (Fig. 3) and the largely unchanged spectra for the A171X and K174X mutants.


Figure 3
View larger version (28K):
[in this window]
[in a new window]

  		FIGURE 3.
Circular dichroism of wild type {alpha}B-crystallin and the C-terminal extension mutants. Far UV CD spectra (205–250 nm) for each protein were the average of four spectra. The far UV CD signal was converted to molar ellipticity expressed as degree/cm2/dmol–1 to normalize for slight differences in molecular mass between the wild type and the other {alpha}B-crystallin constructs. The far UV CD spectra of wild type, A171X, and K174X are similar in shape and magnitude and contained broad minima between 208 and 217 nm. The 450delA/wild type and 464delCT/wild type mixtures show increased negative ellipticity and a shift in minima to 208 nm. Truncation of the C-terminal extension results in the loss of secondary structure reflected by a decrease in negative ellipticity and a shift in wavelength minima (E164X, E165X, Q151X, and Q151X/wild type), with the most dramatic effects seen for Q151X.

 


Figure 4
View larger version (24K):
[in this window]
[in a new window]

  		FIGURE 4.
Thermal stability of wild type and C-terminal extension mutants of {alpha}B-crystallin. The effect of the C-terminal extension mutations on the heat-induced aggregation of {alpha}B-crystallin was measured at 360 nm over the temperature range 25–86 °C. The temperature was increased at a 1 °C/min over 1 h. Wild type and mutant {alpha}B-crystallins were assayed at 0.1 mg/ml. Notice the significantly reduced stability of the E164X, Q151X, and E165X {alpha}B-crystallin mutants.

 
Effect of C-terminal Extension Mutants upon Exposed Hydrophobicity—The probe, bis-ANS, has a low fluorescence quantum yield in aqueous solution, however, this increases dramatically upon binding to surface-exposed hydrophobic regions. As can be seen in Fig. 5, all the {alpha}B-crystallin mutants bind more bis-ANS relative to the wild type {alpha}B-crystallin, except for the Q151X mutant, which binds substantially less. As all the mutants except Q151X {alpha}B-crystallin form oligomers (Fig. 2), we infer from these data that the increase in exposed hydrophobic surfaces arise from changes within their respective oligomeric structures. The reason why Q151X {alpha}B-crystallin binds so little bis-ANS is probably due the combined effects of decreased oligomerization and loss of secondary structure. We tested this by examining the bis-ANS binding properties of the wild type protein under mildly denaturing conditions (2 M guanidinium hydrochloride), which have been shown previously to eject {alpha}B-crystallin from native {alpha}-crystallin oligomers and to cause a significant loss of secondary structure (47). Indeed the presence of the guanidinium hydrochloride greatly reduced the bis-ANS binding to wild type {alpha}B-crystallin, with the fluorescence intensity dropping almost as low as that obtained for Q151X {alpha}B-crystallin alone.

Effect of C-terminal Extension Mutations upon {alpha}B-Crystallin Chaperone Activity—Citrate synthase (Fig. 6A) and insulin (Fig. 6C) chaperone assays were used to determine the effects of the {alpha}B-crystallin C-terminal extension mutations. Our expectation was that the observed chaperone activity would correlate with the effects of the mutations on protein secondary structure and heat stability. We predicted that E164X, E165X, and Q151X would exhibit the least activity in this assay. The chaperone activity achieved by these mutants in a citrate synthase aggregation assay (Fig. 6B) showed that whereas E164X was indeed the worst of all the {alpha}B-crystallin constructs (–57% inhibition) none of the other C-terminal extension constructs performed worse that the wild type protein (100% inhibition). Indeed, the E165X (313%) was slightly better than the wild type protein and Q151X (755%) was one of the best. In fact, the combination of Q151X and wild type {alpha}B-crystallin was the best chaperone in the citrate synthase assay (1263% inhibition).

Another surprise from the citrate synthase chaperone assay was the relative performance of the two frameshift mutants, 450delA and 464delCT, both of which performed better in combination with wild type {alpha}B-crystallin than the wild type {alpha}B-crystallin alone (625 and 216% inhibition, respectively). These data show that the disease-causing mutations in {alpha}B-crystallin (Q151X, 450delA, and 464delCT) all retain significant chaperone activity, surpassing the potential of the wild type protein alone for this client protein in this particular chaperone assay.


Figure 5
View larger version (30K):
[in this window]
[in a new window]

  		FIGURE 5.
Bis-ANS fluorescence binding properties of{alpha}B-crystallin mutants. The effect of the C-terminal mutations upon the relative exposed hydrophobicity was performed using bis-ANS to bind to surface-exposed hydrophobic regions on the mutant and wild type {alpha}B-crystallin. Each protein was analyzed at 1 µM in the presence of a 10-fold molar excess of bis-ANS. The excitation wavelength was 410 nm and emission spectra were collected between 420 and 700 nm. All spectra are the average of 10 individual scans. The resulting exposed hydrophobicity is increased for all mutants relative to the wild type {alpha}B-crystallin, with the exception of the Q151X mutant.

 
In contrast to the results with citrate synthase, all the C-terminal extension mutants performed worse than the wild type {alpha}B-crystallin in the insulin-based chaperone assay (Fig. 6C). In this assay, the three most heat-sensitive {alpha}B-crystallin mutants, E164X, E165X, and Q151X, increased protein aggregation compared with wild type {alpha}B-crystallin (–138, –8, and –45% inhibition, respectively (Fig. 6D)). An equimolar mixture of Q151X and wild type {alpha}B-crystallin (47% inhibition) retained significant chaperone activity of Q151X, but it was still one of the poorer chaperones in this assay. The K174X (93%) and A171X (93%) mutants had chaperone activities that most closely resembled the wild type {alpha}B-crystallin (100%) and even the two frameshift mutants, 450delA and 464delCT, in their respective combinations with wild type {alpha}B-crystallin, still possessed credible activities (68 and 78% inhibition, respectively).

Ability of the Disease-causing {alpha}B-Crystallin Mutants to Inhibit Desmin Filament Aggregation—One of the characteristic histopathological features of the human myopathies caused by some of the mutations in {alpha}B-crystallin under investigation in this study is the presence of aggregates of desmin filaments (9, 12). It was therefore decided to analyze the ability of the {alpha}B-crystallin mutants in this study to prevent desmin filament-filament associations (Fig. 7), using an assay developed to investigate the cell biological effects of the R120G mutation in {alpha}B-crystallin (10).

The assay takes advantage of the fact that intermediate filaments interact with each other in solution (10, 48) and this can be measured by sedimentation assay. The presence of a mutant protein that interacts with desmin filaments, for example, R120G {alpha}B-crystallin, activity encourages more filament-filament associations and therefore increases the proportion of pelletable desmin. Both Q151X and 464delCT {alpha}B-crystallin when mixed with wild type displayed desmin filament associations similar to wild type alone, whereas the 450delA/wild type protein mixture was significantly more effective than R120G {alpha}B-crystallin in inducing this filament association, highlighting the dominant effect of the 450delA mutation over the wild type {alpha}B-crystallin (Fig. 7).

In stark contrast to these results, the Q151X {alpha}B-crystallin was the most effective chaperone of all the disease-causing mutants and was also better than wild type {alpha}B-crystallin in reducing the proportion of pelletable desmin (Fig. 7A). Most of the Q151X mutant co-sedimented with desmin in the pellet fraction (cf. Fig. 7, B and C). Mixing Q151X with wild type {alpha}B-crystallin in an equimolar ratio reduced this binding to desmin filaments (cf. Fig. 7, B and C) and restored the levels of pelletable desmin to those obtained in the presence of wild type {alpha}B-crystallin (Fig. 7A). In contrast, the 450delA mutant was clearly dominant over the wild type {alpha}B-crystallin as there was not only increased binding to the filaments (cf. Fig. 7, B and C), but also a significant increase in the proportion of pelletable desmin (Fig. 7A). We interpret these data to indicate that the increased binding of 450delA {alpha}B-crystallin induces more filament-filament interactions resulting in more desmin in the pellet. Interestingly all the mutant {alpha}B-crystallins exhibited elevated binding to desmin filaments (Fig. 7C), but under these assay conditions (0.1 mg/ml desmin at 37 °C), the Q151X and 450delA {alpha}B-crystallin had opposite effects upon the promotion of filament-filament interactions.

To show that the effects of Q151X {alpha}B-crystallin were not due to an inhibition of desmin filament assembly per se, negatively stained samples were analyzed by electron microscopy (Fig. 7E) and the presence of abundant 10-nm filaments confirmed. When compared with desmin assembled in the presence of wild type {alpha}B-crystallin (Fig. 7D), the absence of {alpha}B-crystallin particles in the Q151X containing sample was also immediately apparent, confirming independently the data in Fig. 2, A and D.

Cytoplasmic Aggregate Formation of Selected {alpha}B-Crystallin Mutants in MCF7 Cells—The in vitro assays show that the Q151X mutant increased some chaperone activities, but also significantly destabilized the protein causing it to aggregate. We then decided to investigate the behavior of Q151X {alpha}B-crystallin when transiently transfected into tissue culture cells (Fig. 8), using MCF7 cells as established in previous studies investigating desmin (49) and {alpha}B-crystallin (10) mutations. MCF7 cells have high endogenous levels of HSP27, a small heat shock protein chaperone that is known to form heterogeneous oligomers with {alpha}B-crystallin (50). The cell line also has little or no endogenous {alpha}B-crystallin (10, 14), thus avoiding the need to tag the protein for subsequent detection. Cells expressing wild type {alpha}B-crystallin (Fig. 8A, green channel), showed a homogeneous cytoplasmic distribution. In contrast, cells expressing the Q151X mutant {alpha}B-crystallin were obvious by the presence of cytoplasmic aggregates that were immunopositive for {alpha}B-crystallin (Fig. 8B). A similar result was also obtained for two other {alpha}B-crystallin constructs, the mutant 464delCT and the C-terminal-truncated {alpha}B-crystallin E164X (Fig. 8, C and D). Our previous data (Figs. 2 and 4) suggest that like Q151X, both were destabilized and prone to self-aggregation and the fact that both also form cytoplasmic aggregates supports this conclusion. Our data also complement a paper published as our manuscript was being reviewed, which found that both Q151X and 464delCT {alpha}B-crystallin formed aggregates in transfected cells (51). To provide an assessment of the solubility of the different {alpha}B-crystallin constructs in populations of transiently transfected MCF7 cells, cell extracts were produced and fractionated into supernatant and pellet fractions by centrifugation prior to analysis by SDS-PAGE and immunoblotting with antibodies to HSP27 and {alpha}B-crystallin (Fig. 8E). Transfected wild type {alpha}B-crystallin was found almost entirely in the soluble fraction (Fig. 8E, lane 1). Transfected Q151X, 464delCT, and E164X, however, were detected almost entirely in the pellet fractions (Fig. 8E, lanes 4, 6, and 8, respectively) with only a small proportion left in the supernatant fractions (Fig. 8E, lanes 3, 5, and 7, respectively). The endogenous HSP27 was unable to prevent the formation of aggregates by the mutant {alpha}B-crystallins and the presence of these aggregates did not cause a significant shift in the solubility of the endogenous HSP27 to the pellet fraction. These data support our hypothesis that the loss of the C-terminal domain, as occurs in the Q151X mutation, dramatically increases the tendency of {alpha}B-crystallin to self-aggregate, even in a cellular environment.


Figure 6
View larger version (45K):
[in this window]
[in a new window]

  		FIGURE 6.
Aggregation of citrate synthase and insulin in the presence of wild type and mutant {alpha}B-crystallins. The effect of wild type and mutant {alpha}B-crystallin on the thermal aggregation of citrate synthase (A and B), over a 30-min period at 42 °C, and reduction-induced aggregation of insulin (C and D), over a 15-min period at 37 °C was measured using OD360 (OD360). A 4:1 molar ratio of substrate:chaperone was used. The relative inhibition of citrate synthase (B) and insulin (D) aggregation by the C-terminal extension mutants was calculated as a percentage of the level of inhibition achieved by wild type {alpha}B-crystallin alone (100% inhibition). These data represented the average (±S.D.) of three independent experiments (see supplementary data Figs. S3 and S4 for the complete data sets).

 


Figure 7
View larger version (131K):
[in this window]
[in a new window]

  		FIGURE 7.
Sedimentation assay to investigate the prevention of desmin filament aggregation in the presence of various {alpha}B-crystallins at 37 °C. A–C shows the % desmin pelleted (A), the % {alpha}B-crystallin wild type and mutants remaining soluble in the presence of desmin (B), and the % of the total {alpha}B-crystallin pelleted in the presence of desmin (C), following low-speed centrifugation (2500 x g). These data were calculated from SDS-PAGE data of the desmin binding assays. D, an example of the data used to calculate these values for wild type, Q151X/wild type, and Q151X {alpha}B-crystallin. These data illustrate the ability of the Q151X {alpha}B-crystallin to prevent desmin filament aggregation. Images obtained by electron microscopy of negatively stained samples of the assembled filaments for desmin assembled in the presence of wild type (E) and Q151X (F){alpha}B-crystallin are shown to show that the addition of both chaperones has not dramatically altered filament morphology or length. Notice the lack of crystallin particles in the Q151X sample. Bar, 100 nm. S, supernatant; P, pellet.

 

   DISCUSSION
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
REFERENCES
 
Removal of the C-terminal Extension Reduces {alpha}B-Crystallin Oligomerization, but Not Chaperone Activity—The consensus view that has emerged from recent studies on mammalian sHSPs is that the C-terminal extension is important for oligomerization and chaperone function (19, 22, 26, 28). The study presented here is the first to investigate the effects of sequentially truncating this domain (Lys174, Ala171, Glu165, and Glu164) upon both aspects for {alpha}B-crystallin. It shows that deletion of the last 5 residues can improve chaperone activity in the citrate synthase assay without dramatically changing the secondary structure or oligomerization of {alpha}B-crystallin. Truncations (E164X, E165X) in the conserved REEK motif (26) decreased chaperone activity and oligomerization, although this coincided with more polydispersity for the oligomer as judged by size exclusion chromatography (Fig. 2). The removal of the C-terminal extension by the Q151X mutation produced a construct with the best chaperone activity profile of all the individual protein clients investigated (Figs. 6 and 7) despite the most significant changes in secondary structure (Fig. 3), bis-ANS binding (Fig. 5), and altered oligomerization (Fig. 2).


Figure 8
View larger version (86K):
[in this window]
[in a new window]

  		FIGURE 8.
Decreased solubility and increased aggregation potential of Q151X {alpha}B-crystallin is revealed by transient transfection into MCF7 cells. A–D, MCF7 cells transiently transfected with wild type (A), Q151X (B), 464delCT (C), or E164X (D) {alpha}B-crystallin were fixed at 24 h post-transfection and processed for immunofluorescence microscopy. The subcellular distribution of {alpha}B-crystallin and keratin were visualized by double labeling with monoclonal anti-keratin (red channel) and polyclonal anti-{alpha}B-crystallin antibodies (green channel). A–D are merged images, showing the superimposition of the green, red, and blue (4',6-diamidino-2-phenylindole staining) channels. Images are individual optical sections acquired using a confocal laser scanning microscope (Zeiss 510). Cells expressing wild type {alpha}B-crystallin (A) showed the expected cytoplasmic distribution of {alpha}B-crystallin. In contrast, cells expressing mutant {alpha}B-crystallin resulted in the formation of cytoplasmic aggregates of {alpha}B-crystallin (B–D). Notice that 464delCT aggregates are scattered throughout the cytoplasm, whereas the Q151X and E164X aggregates locate to the perinuclear region of the cell. Bars, 10 µm. Immunoblotting analysis (E) of {alpha}B-crystallin transiently transfected in MCF7 cells shows a shift in solubility for the mutant {alpha}B-crystallins. At 24 h post-transfection, cells were extracted with detergent buffer followed by centrifugation at 18,000 x g for 10 min at 4 °C. The resulting supernatant (S) and pellet (P) fractions were analyzed by SDS-PAGE followed by immunoblotting analysis using anti-HSP 27 (loading control) and {alpha}B-crystallin antibodies. The blot was developed using enhanced chemiluminescence. Whereas wild type {alpha}B-crystallin was almost entirely soluble (E, lane 1, labeled S), Q151X (lane 4), 464delCT (lane 6), and E164X (lane 8) were found mostly in the pellet fractions (labeled P) of cell extracts. The relative electrophoretic mobility of mutant {alpha}B-crystallins is denoted by the arrowhead ({blacktriangleright}). Like wild type {alpha}B-crystallin, HSP27 was also largely present in the supernatant fractions (E, lanes 2, 4, and 6, labeled P). These data are representative of three experiments.

 
Whereas these results are in broad agreement with the consensus for other mammalian sHSPs, they demonstrate that the removal of the C-terminal extension from residue 151 prevents oligomerization (at concentrations less than 0.1 mg/ml), but not at the expense of chaperone function for {alpha}B-crystallin. Indeed the citroconylation of full-length {alpha}B-crystallin achieves similar results and together with these data strongly support the conclusion that oligomerization is not required for {alpha}B-crystallin chaperone activity (42).

Deletion of the C-terminal Extension by the Q151X Mutation Increases Chaperone Activity for Some Client Proteins—The somewhat surprising observation is that the Q151X mutation actually improved chaperone activity for some client proteins (desmin and citrate synthase), in stark contrast to the effect of removing a similar region from {alpha}A-crystallin where chaperone activity was lost (22, 28).

The C-terminal extension deleted by the Q151X mutation includes the IX(I/V) motif (16), which is part of β-strand 10 (17, 23), that has been shown to be both part of a client protein binding site (19) and an oligomerization sequence (20) in {alpha}B-crystallin. This is removed by all three disease-causing mutations, including Q151X, but retained in the other truncation constructs (Fig. 1). Glycine substitutions in the IX(I/V) motif not only increased oligomerization and polydispersity of {alpha}B-crystallin, but also significantly increased chaperone activity (52). The data we have presented for Q151X {alpha}B-crystallin and the other truncation constructs suggest that the client protein binding site that embraces the IX(I/V) motif (19, 53) is not only dispensable for activity, but that it could actually inhibit chaperone function as its removal actually increased activity (citrate synthase, ~7.5-fold; desmin, ~2-fold).

A three-dimensional model of {alpha}B-crystallin has suggested that the C-terminal extension potentially acts as a "cap" on an important oligomerization and client protein binding site, namely the β3-β8-β9 interface (46). This region also interacts with the β4 strand, which is important in sHSP oligomerization as seen from the crystal structure of HSP16.9 (23), but it is also critical for chaperone activity (46). In fact reducing {alpha}B-crystallin to just its {alpha}-crystallin domain spanning residues 57–157, which still includes the β3-β8-β9 surface, retained chaperone activity, but this construct only formed dimers and could not oligomerize (54). It is easy to explain these observations and also our data on the Q151X {alpha}B-crystallin mutant, in terms of how the removal of this C-terminal extension cap as proposed in the model (46) could allow substrate to bind more readily and thus enhance chaperone function while also decreasing oligomer size. The data we have presented here support this model and also add an interesting dimension. Our data also suggest that the C-terminal extension actually limits the full potential of {alpha}B-crystallin chaperone activity for some client proteins.

Aggregation of {alpha}B-Crystallin Encouraged by the Removal of the C-terminal Extension—The strong tendency of Q151X to aggregate at protein concentrations greater than 0.1 mg/ml and its very low refolding yield (Fig. 1D), suggests another potential role played by the C-terminal extension in preventing the uncontrolled self-aggregation of {alpha}B-crystallin (55). From the available sHSP crystal structures (17, 23), the C-terminal extension is solvent exposed and contributes to the higher order assembly of the oligomer (23, 56–58). In HSP16.9, the IX(I/V) motif from one subunit lays in a hydrophobic groove between β4 and β8 strands of the other interacting monomer. Although {alpha}B-crystallin has similar structural features, including the conserved IX(I/V) motif in its C-terminal extension (Fig. 1A), the oligomers it forms are more polydisperse (55, 59, 60) compared with either HSP16.5 or HSP16.9, suggesting that the precise detail for the interactions of the C-terminal extension in {alpha}B-crystallin will vary, not least due to the different hinge sequences between β-strands 9 and 10 (23). The strong tendency of Q151X {alpha}B-crystallin to aggregate suggests that the C-terminal extension actually prevents such potential errant associations to favor instead oligomerization.

Reduced Protein Stability and Uncontrolled Self-aggregation Underlies the Molecular Basis of the Q151X, 450delA, and 464delCT Mutations—The loss of the C-terminal extension due to the Q151X mutation in {alpha}B-crystallin dramatically altered the secondary (Fig. 3) and tertiary structure of the protein (Fig. 2). This mutant was significantly destabilized as seen from the heat stability assay (Fig. 4) and showed a dramatic increase in the tendency to self-aggregate in vitro (Fig. 1) and in vivo (Fig. 8). Only a small proportion of Q151X {alpha}B-crystallin (~1%, Fig. 1D) remained soluble after refolding. Even in the presence of equimolar wild type {alpha}B-crystallin, the mixture had significantly altered secondary structure (Fig. 2), which affected {alpha}B-crystallin oligomerization (Fig. 3) and reduced refold yields (Fig. 1D). The Q151X mutation was dominant over the wild type protein in its effects upon heat stability, solubility, and secondary structure. These data suggest that the strong tendency to self-aggregate as a result of reduced stability is potentially an important factor in disease development.

Our data for both 450delA and 464delCT also suggest that it is a similar loss in protein stability that causes cataract and myofibrillar myopathy, respectively. Both mutants can only be refolded in the presence of wild type {alpha}B-crystallin and even then the temperature stabilities of the mixtures are reduced by some 20 °C compared with the wild type protein alone. Both the 450delA and 464delCT mutations introduced novel C-terminal peptides that have no homology to the existing C-terminal extension of {alpha}B-crystallin (Fig. 1A). Both mutations changed the oligomerization of wild type {alpha}B-crystallin and neither mutant/wild type mixture was an effective chaperone in either the desmin (Fig. 7) or insulin (Fig. 6, C and D) assays. Indeed, the 450delA mutation actively promoted filament-filament interactions for desmin, as reported previously for R120G {alpha}B-crystallin (10) and, under the assay conditions here, 450delA was more efficient than R120G in this activity. Therefore the loss of chaperone activity coupled with sequestration by client proteins could both contribute to the development of disease in the case of these two mutants. We suggest, however, that the aggregation of {alpha}B-crystallin is a key feature that offers potential for gain of function via its amyloidogenic potential (61).

The most difficult observation to explain regarding the Q151X mutation is its muscle-specific effect, which restricts the pathology to myofibillar myopathy (18). In fact all three disease-causing mutations in the C-terminal extension of {alpha}B-crystallin (Q151X, 450delA, and 464delCT) are restricted in their pathology to either the lens (450delA (15)) or muscle (Q151X, 464delCT; (18)) and yet {alpha}B-crystallin is very highly expressed in both tissues (5). This is a familiar trend for {alpha}B-crystallin mutations and even the most recently published mutation, D140N, causes only lens cataract (62). Thus far, R120G {alpha}B-crystallin is the only mutation that has produced both lens and muscle pathologies (9), but this is not to say that subclinical pathology can be totally excluded for the other mutations, including Q151X, as tissue biopsies from apparently unaffected tissues were not analyzed. Aggregation is a key histopathological feature of the Q151X mutation (18) concurring with our transient transfection and cell fractionation studies (Fig. 8) and so, this provides a plausible mechanism to support a potential dominant negative effect of the mutation by inhibiting the chaperone function of wild type {alpha}B-crystallin via coaggregation with mutant Q151X as implicated from our in vitro studies (Fig. 1).


   FOOTNOTES
 
* This work was supported by a Biotechnology and Biological Sciences Research Council (BBSRC) and ImmunoDiagnostics Systems BBSRC CASE award (to V. H. H.) and National Institutes of Health NINDS Grant P01NS42803 (to R. A. Q.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement"in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Back

Formula The on-line version of this article (available at http://www.jbc.org) contains supplemental Figs. S1–S4. Back

1 To whom correspondence should be addressed. Fax: 44-191-334-1201; E-mail: r.a.quinlan{at}durham.ac.uk.

2 The abbreviations used are: sHSP, small heat shock protein; bis-ANS, 4,4'-dianilino-1,1'-binaphthyl-5,5'-disulfonic acid; MWCO, molecular weight cut off; SEC, size exclusion chromatography. Back


   ACKNOWLEDGMENTS
 
We thank Terry Gibbons for technical support and Ming Der Perng for helpful discussions. We thank Cait MacPhee (Dept. of Physics, University of Edinburgh) for discussions and David Dixon for mass spectrometry analyses of recombinant proteins.



   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Morner, C. (1894) Hoppe-Seyler's Z. Physiol. Chem. 18, 61–106
  2. Bloemendal, H., and de Jong, W. W. (1991) Prog. Nucleic Acids Res. Mol. Biol. 41, 259–281[Medline] [Order article via Infotrieve]
  3. Kato, K., Shinohara, H., Kurobe, N., Goto, S., Inaguma, Y., and Ohshima, K. (1991) Biochim. Biophys. Acta 1080, 173–180[CrossRef][Medline] [Order article via Infotrieve]
  4. Iwaki, T., Kume-Iwaki, A., Liem, R. K., and Goldman, J. E. (1991) Kidney Int. 40, 52–56[Medline] [Order article via Infotrieve]
  5. Kato, K., Shinohara, H., Kurobe, N., Inaguma, Y., Shimizu, K., and Ohshima, K. (1991) Biochim. Biophys. Acta 1074, 201–208[Medline] [Order article via Infotrieve]
  6. Klemenz, R., Frohli, E., Steiger, R. H., Schafer, R., and Aoyama, A. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 3652–3656[Abstract/Free Full Text]
  7. Horwitz, J. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 10449–10453[Abstract/Free Full Text]
  8. Kappe, G., Verschuure, P., Philipsen, R. L., Staalduinen, A. A., Van de Boogaart, P., Boelens, W. C., and De Jong, W. W. (2001) Biochim. Biophys. Acta 1520, 1–6[Medline] [Order article via Infotrieve]
  9. Vicart, P., Caron, A., Guicheney, P., Li, Z., Prevost, M. C., Faure, A., Chateau, D., Chapon, F., Tome, F., Dupret, J. M., Paulin, D., and Fardeau, M. (1998) Nat. Genet. 20, 92–95[CrossRef][Medline] [Order article via Infotrieve]
  10. Perng, M. D., Wen, S. F., van den IJssel, P., Prescott, A. R., and Quinlan, R. A. (2004) Mol. Biol. Cell 15, 2335–2346[Abstract/Free Full Text]
  11. Goldfarb, L. G., Park, K. Y., Cervenakova, L., Gorokhova, S., Lee, H. S., Vasconcelos, O., Nagle, J. W., Semino-Mora, C., Sivakumar, K., and Dalakas, M. C. (1998) Nat. Genet. 19, 402–403[CrossRef][Medline] [Order article via Infotrieve]
  12. Schroder, R., Vrabie, A., and Goebel, H. H. (2007) J. Cell. Mol. Med. 11, 416–426[CrossRef][Medline] [Order article via Infotrieve]
  13. Nicholl, I. D., and Quinlan, R. A. (1994) EMBO J. 13, 945–953[Medline] [Order article via Infotrieve]
  14. Perng, M. D., Cairns, L., van den IJssel, P., Prescott, A., Hutcheson, A. M., and Quinlan, R. A. (1999) J. Cell Sci. 112, 2099–2112[Abstract]
  15. Berry, V., Francis, P., Reddy, M. A., Collyer, D., Vithana, E., MacKay, I., Dawson, G., Carey, A. H., Moore, A., Bhattacharya, S. S., and Quinlan, R. A. (2001) Am. J. Hum. Genet. 69, 1141–1145[CrossRef][Medline] [Order article via Infotrieve]
  16. de Jong, W. W., Caspers, G. J., and Leunissen, J. A. (1998) Int. J. Biol. Macromol. 22, 151–162[CrossRef][Medline] [Order article via Infotrieve]
  17. Kim, K. K., Kim, R., and Kim, S. H. (1998) Nature 394, 595–599[CrossRef][Medline] [Order article via Infotrieve]
  18. Selcen, D., and Engel, A. G. (2003) Ann. Neurol. 54, 804–810[CrossRef][Medline] [Order article via Infotrieve]
  19. Ghosh, J. G., Estrada, M. R., and Clark, J. I. (2005) Biochemistry 44, 14854–14869[CrossRef][Medline] [Order article via Infotrieve]
  20. Ghosh, J. G., and Clark, J. I. (2005) Protein Sci. 14, 684–695[CrossRef][Medline] [Order article via Infotrieve]
  21. Inagaki, N., Hayashi, T., Arimura, T., Koga, Y., Takahashi, M., Shibata, H., Teraoka, K., Chikamori, T., Yamashina, A., and Kimura, A. (2006) Biochem. Biophys. Res. Commun. 342, 379–386[CrossRef][Medline] [Order article via Infotrieve]
  22. Andley, U. P., Mathur, S., Griest, T. A., and Petrash, J. M. (1996) J. Biol. Chem. 271, 31973–31980[Abstract/Free Full Text]
  23. van Montfort, R. L., Basha, E., Friedrich, K. L., Slingsby, C., and Vierling, E. (2001) Nat. Struct. Biol. 8, 1025–1030[CrossRef][Medline] [Order article via Infotrieve]
  24. Stamler, R., Kappe, G., Boelens, W., and Slingsby, C. (2005) J. Mol. Biol. 353, 68–79[CrossRef][Medline] [Order article via Infotrieve]
  25. Kim, R., Lai, L., Lee, H. H., Cheong, G. W., Kim, K. K., Wu, Z., Yokota, H., Marqusee, S., and Kim, S. H. (2003) Proc. Natl. Acad. Sci. U. S. A. 100, 8151–8155[Abstract/Free Full Text]
  26. Rajan, S., Chandrashekar, R., Aziz, A., and Abraham, E. C. (2006) Biochemistry 45, 15684–15691[CrossRef][Medline] [Order article via Infotrieve]
  27. Treweek, T. M., Ecroyd, H., Williams, D. M., Meehan, S., Carver, J. A., and Walker, M. J. (2007) PLoS ONE 2, e1046[CrossRef]
  28. Thampi, P., and Abraham, E. C. (2003) Biochemistry 42, 11857–11863[CrossRef][Medline] [Order article via Infotrieve]
  29. Perng, M. D., Muchowski, P. J., van den IJssel, P., Wu, G. J. S., Clark, J. I., and Quinlan, R. A. (1999) J. Biol. Chem. 274, 33235–33243[Abstract/Free Full Text]
  30. Horwitz, J., Huang, Q. L., Ding, L., and Bova, M. P. (1998) Methods Enzymol. 290, 365–383[Medline] [Order article via Infotrieve]
  31. Quinlan, R. A., Moir, R. D., and Stewart, M. (1989) J. Cell Sci. 93, 71–83[Abstract/Free Full Text]
  32. Laemmli, U. (1970) Nature 277, 680–685
  33. Plater, M. L., Goode, D., and Crabbe, M. J. (1996) J. Biol. Chem. 271, 28558–28566[Abstract/Free Full Text]
  34. He, S., Pan, S., Wu, K., Amster, I. J., and Orlando, R. (1995) J. Mass Spectrom. 30, 424–431[CrossRef]
  35. Smith, J. B., Shun-Shin, G. A., Sun, Y., Miesbauer, L. R., Yang, Z., Yang, Z., Zhou, X., Schwedler, J., and Smith, D. L. (1995) J. Protein Chem. 14, 179–188[CrossRef][Medline] [Order article via Infotrieve]
  36. Jimenez-Asensio, J., Colvis, C. M., Kowalak, J. A., Duglas-Tabor, Y., Datiles, M. B., Moroni, M., Mura, U., Rao, C. M., Balasubramanian, D., Janjani, A., and Garland, D. (1999) J. Biol. Chem. 274, 32287–32294[Abstract/Free Full Text]
  37. Colvis, C. M., Duglas-Tabor, Y., Werth, K. B., Vieira, N. E., Kowalak, J. A., Janjani, A., Yergey, A. L., and Garland, D. L. (2000) Electrophoresis 21, 2219–2227[CrossRef][Medline] [Order article via Infotrieve]
  38. Ueda, Y., Duncan, M. K., and David, L. L. (2002) Investig. Ophthalmol. Vis. Sci. 43, 205–215[Abstract/Free Full Text]
  39. Van Kleef, S. M., Willems-Thijssen, W., and Hoenders, H. J. (1976) Eur. J. Biochem. 66, 477–483[Medline] [Order article via Infotrieve]
  40. Thampi, P., Hassan, A., Smith, J. B., and Abraham, E. C. (2002) Investig. Ophthalmol. Vis. Sci. 43, 3265–3272[Abstract/Free Full Text]
  41. Ueda, Y., Fukiage, C., Shih, M., Shearer, T. R., and David, L. L. (2002) Mol. Cell. Proteomics 1, 357–365[Abstract/Free Full Text]
  42. Horwitz, J., Huang, Q., and Ding, L. (2004) Exp. Eye Res. 79, 817–821[CrossRef][Medline] [Order article via Infotrieve]
  43. Bova, M. P., Yaron, O., Huang, Q., Ding, L., Haley, D. A., Stewart, P. L., and Horwitz, J. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 6137–6142[Abstract/Free Full Text]
  44. Sreelakshmi, Y., and Sharma, K. K. (2006) Mol. Vis. 12, 581–587[Medline] [Order article via Infotrieve]
  45. Pasta, S. Y., Raman, B., Ramakrishna, T., and Rao, Ch. M. (2003) J. Biol. Chem. 278, 51159–51166[Abstract/Free Full Text]
  46. Ghosh, J. G., Estrada, M. R., and Clark, J. I. (2006) Biochemistry 45, 9878–9886[CrossRef][Medline] [Order article via Infotrieve]
  47. Doss-Pepe, E. W., Carew, E. L., and Koretz, J. F. (1998) Exp. Eye Res. 67, 657–679[CrossRef][Medline] [Order article via Infotrieve]
  48. Bousquet, O., Ma, L., Yamada, S., Gu, C., Idei, T., Takahashi, K., Wirtz, D., and Coulombe, P. A. (2001) J. Cell Biol. 155, 747–754[Abstract/Free Full Text]
  49. Munoz-Marmol, A. M., Strasser, G., Isamat, M., Coulombe, P. A., Yang, Y., Roca, X., Vela, E., Mate, J. L., Coll, J., Fernandez-Figueras, M. T., Navas-Palacios, J. J., Ariza, A., and Fuchs, E. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 11312–11317[Abstract/Free Full Text]
  50. Zantema, A., Verlaan-De Vries, M., Maasdam, D., Bol, S., and van der Eb, A. (1992) J. Biol. Chem. 267, 12936–12941[Abstract/Free Full Text]
  51. Simon, S., Fontaine, J. M., Martin, J. L., Sun, X., Hoppe, A. D., Welsh, M. J., Benndorf, R., and Vicart, P. (2007) J. Biol. Chem. 282, 34276–34287[Abstract/Free Full Text]
  52. Pasta, S. Y., Raman, B., Ramakrishna, T., and Rao, Ch. M. (2004) Mol. Vis. 10, 655–662[Medline] [Order article via Infotrieve]
  53. Ghosh, J. G., Houck, S. A., and Clark, J. I. (2008) Int. J. Biochem. Cell Biol. 40, 954–967[CrossRef][Medline] [Order article via Infotrieve]
  54. Feil, I. K., Malfois, M., Hendle, J., van Der Zandt, H., and Svergun, D. I. (2001) J. Biol. Chem. 276, 12024–12029[Abstract/Free Full Text]
  55. Aquilina, J. A., Benesch, J. L., Ding, L. L., Yaron, O., Horwitz, J., and Robinson, C. V. (2004) J. Biol. Chem. 279, 28675–28680[Abstract/Free Full Text]
  56. White, H. E., Orlova, E. V., Chen, S., Wang, L., Ignatiou, A., Gowen, B., Stromer, T., Franzmann, T. M., Haslbeck, M., Buchner, J., and Saibil, H. R. (2006) Structure 14, 1197–1204[Medline] [Order article via Infotrieve]
  57. Kennaway, C. K., Benesch, J. L., Gohlke, U., Wang, L., Robinson, C. V., Orlova, E. V., Saibil, H. R., and Keep, N. H. (2005) J. Biol. Chem. 280, 33419–33425[Abstract/Free Full Text]
  58. Kim, R., Kim, K. K., Yokota, H., and Kim, S. H. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 9129–9133[Abstract/Free Full Text]
  59. Haley, D. A., Bova, M. P., Huang, Q. L., McHaourab, H. S., and Stewart, P. L. (2000) J. Mol. Biol. 298, 261–272[CrossRef][Medline] [Order article via Infotrieve]
  60. Haley, D. A., Horwitz, J., and Stewart, P. L. (1998) J. Mol. Biol. 277, 27–35[CrossRef][Medline] [Order article via Infotrieve]
  61. Meehan, S., Knowles, T. P., Baldwin, A. J., Smith, J. F., Squires, A. M., Clements, P., Treweek, T. M., Ecroyd, H., Tartaglia, G. G., Vendruscolo, M., Macphee, C. E., Dobson, C. M., and Carver, J. A. (2007) J. Mol. Biol. 372, 470–484[CrossRef][Medline] [Order article via Infotrieve]
  62. Liu, Y., Zhang, X., Luo, L., Wu, M., Zeng, R., Cheng, G., Hu, B., Liu, B., Liang, J. J., and Shang, F. (2006) Investig. Ophthalmol. Vis. Sci. 47, 1069–1075[Abstract/Free Full Text]

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?



This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Supplemental Data
Right arrow All Versions of this Article:
283/16/10500    most recent
M706453200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hayes, V. H.
Right arrow Articles by Quinlan, R. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hayes, V. H.
Right arrow Articles by Quinlan, R. A.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2008 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement